Skip to main content
. 2021 Jun 15;6(4):100171. doi: 10.1016/j.esmoop.2021.100171

Table 1.

Main clinical and response parameters

No. patients No. events Median PFS, months (95% CI) P No. events Median OS, months (95% CI) P
Overall 46 19 nr — 9 142.6 (103.1-146.2) —
Sex
 Male 20 8 nr — 4 143.5 (103.1-146.2) —
 Female 26 11 74.5 (27.5-nr) 0.803 5 142.6 (85.9-142.6) 0.442
Therapy
 90Y-DOTATOC 12 5 74.5 (8.4-nr) — 2 92.1 (57.1-92.1) —
 177Lu-DOTATATE 34 14 nr 0.678 7 143.5 (103.1-146.2) 0.192
Origin
 Sympathetic 16 11 27.5 (14.5-51.5) — 7 142.6 (76.1-146.2) —
 Parasympathetic 30 8 nr 0.0005a 2 nr 0.104
Symptomatic
 No 33 11 nr 4 142.6 (142.6-146.2)
 Yes 13 8 27.5 (8.4-nr) 0.027a 5 103.1 (25.5-143.5) 0.099
Mutation
 No (wild-type) 16 7 51.5 (27.5-nr) 1 Nr —
 Yes (SDHD/SDHB) 20 4 nr 0.030a 0 Nr 0.248
Liver lesions
 0 38 15 nr — 7 142.6 (92.1-146.2) —
 ≥1 8 4 nr 0.359 2 143.5 (76.1-143.5) 0.753
Bone lesions
 0 27 9 nr 3 142.6 (103.1-142.6)
 ≥1 19 10 48.5 (22.5-nr) 0.062 6 143.5 (57.1-146.2) 0.586

CI, confidence interval; nr, not reached; OS, overall survival; PFS, progression-free survival

Overall median follow-up: 73 months (range 5-146 months).

Median follow-up 177Lu: 73 months (range 6-146 months); 90Y: 76 months (range 5-91 months).